المؤلفون: Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group

المساهمون: Group, Com-COV2 Study

المصدر: Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5

مصطلحات موضوعية: Male, qv_268.5, wa_115, COVID-19/prevention & control, Adjuvants, Vaccine/administration & dosage, qw_806, qw_805, Immunogenicity, Vaccine, Medicine, General & Internal, General & Internal Medicine, parasitic diseases, Humans, Single-Blind Method, 11 Medical and Health Sciences, Aged, COVID-19 Vaccines/administration & dosage, Science & Technology, qv_4, Vaccination/adverse effects, mRNA Vaccines/administration & dosage, Articles, General Medicine, Middle Aged, United Kingdom, Com-COV2 Study Group, 2019-nCoV Vaccine mRNA-1273/administration & dosage, wf_140, qw_160, Female, BNT162 Vaccine/administration & dosage, Life Sciences & Biomedicine, Immunization, Secondary/adverse effects, ChAdOx1 nCoV-19/administration & dosage

وصف الملف: application/pdf; PDF; text

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5